Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism;Estudio multicéntrico, prospectivo, de comparación del tratamiento de la tromboembolia pulmonar submasiva con enoxaparina y heparina no fraccionada

Archivos de Bronconeumologia

Volumn 39, Issue 8, 2003, Pages 341-345

  Perez de Llano L A ^a   Baloira Villar, A ^b   Veres Racamonde, A ^a   Veiga, F ^a   Golpe Gomez R ^c   Pajuelo Fernandez F ^d  

^a HOSPITAL XERAL CALDE   (Spain)

^b HOSPITAL MONTECELO   (Spain)

^c Hospital Comarcal de Monforte   (Spain)

^d Aventis Pharma   (Spain)

Author keywords

Enoxaparin; Heparin: unfractionated; Low molecular weight; Pulmonary thromboembolism

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; ENOXAPARIN; ERYTHROMYCIN; HEPARIN; METRONIDAZOLE;

ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

EID: 0042381869     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13049952     Document Type: Article

References (16)

1. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects, low-molecular-weight heparin versus unfractionated heparin. Haemostasis 1998:28 (Suppl 3):8-16.
2. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800-9.
3. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85:1380-9.
4. Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-5.
5. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
6. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9.
7. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160:229-36.
8. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83:209-11.
9. Van der Heijden JF, Prins MH, Buller HR. Low-molecular-weight heparins: are they interchangeable? Haemostasis 2000;30(Suppl 2):148-57; discussion 146-7.
10. Monreal Bosch M. Tratamiento del embolismo pulmonar submasivo de bajo peso molecular. Med Clin (Barc) 2000;115: 943-6.
11. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990;263:2753-9.
12. Stein PD, Huang H, Afzal A, Noor HA. Incidence of acute pulmonary embolism in a general hospital: relation to age, sex, and race. Chest 1999;116:909-13.
13. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-5.
14. Pinede L, DuhaLit P, Cucherat M, Ninet J, Pasquier J, Boissel JP. Comparison of long versus short duration anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomised, controlled trials. J Intern Med 2000;247:553-6.
15. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
16. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.